Yuyu Pharma, Inc. (KRX:000220)
South Korea · Delayed Price · Currency is KRW 3,690.00
+40.00 (1.10%)
Nov 2, 2026, 3:30 PM KST
Yuyu Pharma Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 144,371 | 140,885 | 133,147 | 137,210 | 138,881 | 115,655 |
Revenue Growth | 6.69% | 5.81% | -2.96% | -1.20% | 20.08% | 17.87% |
Gross Profit Gross Profit Growth | 55,686 | 53,586 | 51,369 | 48,527 | 52,966 | 45,088 |
Operating Income Operating Income Growth | 13,162 | 11,019 | 12,582 | -748.94 | -592.11 | 1,200 |
Net Income Net Income Growth | 12,180 | 7,830 | 8,410 | -6,303 | -6,273 | -2,499 |
Earnings Per Share EPS Growth | 694.87 | 480.78 | 512.56 | -387.43 | -378.31 | -157.00 |
EPS Growth | 150.90% | -6.20% | - | - | - | - |
Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Yuyu Pharmaceutical Yuyu Pharmaceutical Growth | 96,721 |
Yuyu Healthcare Yuyu Healthcare Growth | 38,280 |
Yuyu Medicals Yuyu Medicals Growth | 6,118 |
Consolidation Adjustment Consolidation Adjustment Growth | -234.12 |
Total Total Growth | 140,885 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 27,865 | 32,705 | 42,650 | 32,354 | 30,778 | 50,263 |
Total Debt Total Debt Growth | 28,056 | 27,923 | 33,644 | 39,407 | 39,276 | 39,166 |
Net Cash (Debt) Net Cash Growth | -191.17 | 4,783 | 9,005 | -7,053 | -8,499 | 11,097 |
Net Cash Growth | - | -46.89% | - | - | - | 1907.08% |
Net Cash Per Share Net Cash Per Share Growth | -9.48 | 237.87 | 535.91 | -433.55 | -512.57 | 695.34 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 21,049 | 15,877 | 24,950 | 420.86 | -6,229 | 4,509 |
Capital Expenditures CapEx Growth | -15,024 | -8,253 | -7,112 | -4,514 | -5,283 | -6,073 |
Free Cash Flow Free Cash Flow Growth | 6,026 | 7,625 | 17,838 | -4,094 | -11,512 | -1,565 |
Free Cash Flow Growth | -46.39% | -57.26% | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 38.57% | 38.04% | 38.58% | 35.37% | 38.14% | 38.98% |
Operating Margin | 9.12% | 7.82% | 9.45% | -0.55% | -0.43% | 1.04% |
Pretax Margin | 9.09% | 6.73% | 7.50% | -3.97% | -2.74% | -0.33% |
Profit Margin | 8.44% | 5.56% | 6.32% | -4.59% | -4.52% | -2.16% |
FCF Margin | 4.17% | 5.41% | 13.40% | -2.98% | -8.29% | -1.35% |
Fiscal Year | Current | FY 2025 |
|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 |
Dividend Per Share Dividend Per Share Growth | 115.000 | 115.000 |
Dividend Per Share Growth | 15.00% | - |
Dividend Yield | 3.12% | 2.55% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.31 | 9.08 | 8.67 | - | - | - |
Forward PE | - | 21.92 | 21.92 | 21.92 | 21.92 | 21.92 |
P/FCF Ratio | 9.64 | 9.32 | 4.09 | - | - | - |
PS Ratio | 0.40 | 0.51 | 0.55 | 0.62 | 0.74 | 1.13 |